Fenwick & West represented Veracyte, Inc. (Nasdaq: VCYT), a pioneering genomic diagnostics company, in its public offering of 6,325,000 shares of its common stock, including 825,000 shares upon full exercise of the underwriters’ option, at an offering price of $23.25 per share. The net proceeds to Veracyte were approximately $137.9 million, after deducting underwriting discounts and commissions and estimated offering expenses. Morgan Stanley and SVB Leerink are acting as lead book-running managers for the offering. William Blair is acting as a book-running manager and BTIG and Janney Montgomery Scott are acting as co-managers.
The Fenwick transaction team included corporate lawyers Doug Cogen, Rob Freedman, Ran Ben-Tzur, Michael Shaw, Veronica Zavala and Vincent Sheu.